A closely watched Phase 3 strategy pairing an antibody-drug conjugate with an immune checkpoint inhibitor in PD-L1-high metastatic lung cancer fell short. Sacituzumab govitecan, combined with pembrolizumab, did not achieve a statistically significant improvement in progression-free survival, complicating the outlook for ADC-plus-immunotherapy first-line regimens.